PharmaMar’s Aplidin Back On EMA’s Agenda After Conflict Of Interest Controversy

 
• By Neena Brizmohun
  
Business people discuss financial report in charts diagrams and graphs
The EMA is re-evaluating the marketing application for Aplidin (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from EU CHMP

More from Geography